What Slowdown? Chinese Maker Splashing Big On Promotion To Bolster Prices, Growth
This article was originally published in PharmAsia News
Executive Summary
Could the economic slowdown in China actually translate into opportunities for domestic drug makers? A recent filing for an initial public offering reveals at least one company is forging full speed ahead by spending big on promotion and planning to add over a thousand sales reps, as it looks to shore up product prices and move deeper into the county-level sector.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.